IFP Advisors, Inc - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.

Quarter-by-quarter ownership
IFP Advisors, Inc ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$14,389
-70.7%
317
-60.3%
0.00%0.0%
Q2 2023$49,184
+80.9%
798
+97.0%
0.00%0.0%
Q1 2023$27,188
+41093.9%
405
-47.8%
0.00%
-50.0%
Q4 2022$66
-99.9%
776
-29.3%
0.00%0.0%
Q3 2022$88,000
-4.3%
1,098
-7.0%
0.00%
-33.3%
Q2 2022$92,000
-37.4%
1,181
-40.7%
0.00%
+50.0%
Q1 2022$147,000
+153.4%
1,993
+158.8%
0.00%
+100.0%
Q4 2021$58,000
-30.1%
770
+4.1%
0.00%
-50.0%
Q3 2021$83,000
-37.6%
740
-10.1%
0.00%
-33.3%
Q2 2021$133,000
+27.9%
823
-3.6%
0.00%
+50.0%
Q1 2021$104,000
-14.0%
854
+7.2%
0.00%
-60.0%
Q4 2020$121,000
+77.9%
797
-2.9%
0.01%
+25.0%
Q3 2020$68,000
+41.7%
821
+30.1%
0.00%0.0%
Q2 2020$48,000
+77.8%
631
+2.4%
0.00%
+33.3%
Q1 2020$27,000
+237.5%
616
+431.0%
0.00%
+200.0%
Q4 2019$8,000
+33.3%
116
-17.1%
0.00%
Q3 2019$6,000
+500.0%
140
+250.0%
0.00%
Q1 2019$1,000
-94.7%
40
-94.4%
0.00%
-100.0%
Q4 2018$19,000
-38.7%
720
+2.1%
0.00%0.0%
Q3 2018$31,000
-38.0%
705
-17.4%
0.00%
-50.0%
Q2 2018$50,000
+455.6%
853
+113.2%
0.00%
Q1 2018$9,0000.0%4000.0%0.00%
Q4 2017$9,000
+800.0%
400
+900.0%
0.00%
Q1 2016$1,000400.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2023
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders